Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 9/20 | 0.45 |
| ▸ | LOX | P28300 | 6/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | CBFB | Q13951 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183827 | 0.92 | LOXL2 (0.46) | LOXL2LOXRECQLACACBCBFB | |
| SCHEMBL13490772 | 0.85 | LOXL2 (0.46) | LOXL2LOXACACB | |
| SCHEMBL4934891 | 0.83 | LOXL2 (0.67) | LOXL2LOX | |
| SCHEMBL17752 | 0.80 | LOXL2 (0.67) | LOXL2LOXRECQLACACBCBFB | |
| SCHEMBL29841247 | 0.80 | LOXL2 (0.67) | LOXL2LOXRECQLACACBCBFB | |
| SCHEMBL2940362 | 0.79 | RECQL (0.50) | LOXL2LOXRECQLACACBMAOA | |
| SCHEMBL8278931 | 0.77 | UHRF1 (0.42) | LOXL2LOXACACBNPC1RAB9A | |
| SCHEMBL1911369 | 0.77 | ALDH1A1 (0.36) | LOXL2LOXCBFBFFAR4POLB | |
| SCHEMBL1051073 | 0.76 | DYRK1A (0.37) | LOXL2LOXACACBDYRK1AFFAR4 | |
| SCHEMBL3072454 | 0.75 | MTNR1A (0.42) | CBFBFFAR4NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| WO-2006074924-A1 | 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | LOXL2 4638/4885LOX 2174/4885RECQL 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.